Pharm
Levetiracetam
search
Levetiracetam
, Keppra, Spiritam
Indications
Status Epilepticus
Seizure Prophylaxis
Partial Seizure
s or Focal onset
Seizure
s (FDA Approved for adjunctive therapy)
Juvenile Myoclonic
Epilepsy
(FDA approved for ages >12 years for adjunctive therapy)
Primary
Generalized Tonic Clonic Seizure
s (FDA approved for ages >6 years for adjunctive therapy)
Myoclonus
(adults, off label)
Mechanism
Broad spectrum Pyrrolidine anticonvulsant, with activity isolated to the synaptic plasma membrane of CNS
Neuron
s
Decreases burst
Neuron
firing (and decreased
Seizure
propagation) without
Neuron
normal excitability
Binds
Glycoprotein
2A at the synaptic
Vesicle
and may alter
Vesicle
fusion
May also affect
Gamma-Aminobutyric Acid
(
GABA
)
Dosing
Status Epilepticus
Dose: 60 mg/kg IV (or 2.5 g in adults, up to 4.5 g maximum) over 5 to 15 min for single dose
Dosing
Seizure Prophylaxis
in Adults
Target serum concentration: 12 to 46 mcg/ml
Immediate Release (Keppra, Spiritam)
Start: 500 mg orally or IV twice daily
Titrate every 2 weeks, increasing by 1000 mg/day divided twice daily
Typical target dose: 3000 mg/day (or 80 mg/kg/day) divided twice daily
Maximum: 3000 mg/day (higher doses do not increase efficacy)
Extended Release (Keppra XR for
Partial Seizure
s)
Start 1000 mg orally daily
Titrate every 2 weeks, increasing by 1000 mg/day
Typical target dose: 3000 mg/day (or 80 mg/kg/day)
Maximum: 3000 mg/day (higher doses do not increase efficacy)
Intravenous infusion dose is bioequivalent to oral dose
Load: 20-30 mg/kg IV at 5 mg/kg/min
Dosing
Seizure Prophylaxis
in Children
Age 1 to 6 months (Keppra Solution, oral dosing only)
Start 14 mg/kg/day divided orally twice daily
Increase every 2 weeks by 14 mg/kg/day divided twice daily
Target dose: 42 mg/kg/day divided twice daily
Age 6 months to 4 years (Keppra Solution, oral dosing only)
Start 20 mg/kg/day divided orally twice daily
Increase every 2 weeks by 20 mg/kg/day divided twice daily
Target dose: 50 mg/kg/day divided twice daily
Age 4 to 16 years (oral dosing only)
Keppra Solution
Start 20 mg/kg/day divided orally twice daily
Increase every 2 weeks by 20 mg/kg/day divided twice daily
Target dose: 60 mg/kg/day divided twice daily
Keppra tablets: Weight 20 to 40 kg
Start: 250 mg orally twice daily
Titrate every 2 weeks, increasing by 500 mg/day divided twice daily
Typical target dose: 1500 mg/day divided twice daily
Maximum: 1500 mg/day
Keppra tablets: Weight >40 kg
Start: 500 mg orally twice daily
Titrate every 2 weeks, increasing by 1000 mg/day divided twice daily
Typical target dose: 3000 mg/day divided twice daily
Maximum: 3000 mg/day (higher doses do not increase efficacy)
Age >16 years
Use adult dosing (IV or oral)
Adverse Effects
Most common
Fatigue
or Weakness
Somnolence
Dizziness
or
Vertigo
Psychiatric symptoms or Behavioral Changes (common, may limit usage)
Agitation
or hostility
Emotional lability
Anxiety
Depressed mood
Other symptoms
Irritability
Rash
Safety
Safe in children
Pregnancy Category C
Unknown safety in
Lactation
Metabolism
Rapid oral absorption
Renal Excretion
Decrease dose in renal
Impairment
Drug Interactions
May result in toxicity if used with carbamezepine
Low risk for other
Drug Interaction
s
Resources
Levetiracetam
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f65ec19d-b90e-452e-b761-c68b1cf2c892
References
LoVecchio and Pringle (2018) Crit Dec Emerg Med 32(12): 28
(2022) Presc Lett, Resource #361206, Antiseizure Medications
Olson (2020) Clinical
Pharmacology
, Medmaster Miami, p. 56-7
Hamilton (2020) Tarascon Pocket Pharmacopoeia
Liu (2017) Am Fam Physician 96(2): 87-96 [PubMed]
Type your search phrase here